Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD. - Wikidata - wikimedia - TriplyDB

Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.

Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.

http://www.wikidata.org/entity/Q37376330

about

ADHD drugs and serious cardiovascular events in children and young adults Toxicity of amphetamines: an update ADHD medications and risk of serious cardiovascular events in young and middle-aged adults.Advances in understanding and treating ADHD Long-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challenges Pharmacoepidemiological safety studies in children: a systematic review Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide prospective cohort study.An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review.European guidelines on managing adverse effects of medication for ADHD.Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks?Adult attention-deficit/hyperactivity disorder treatment and cardiovascular implications.Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.Abuse and dependence liability analysis of methylphenidate in the spontaneously hypertensive rat model of attention-deficit/hyperactivity disorder (ADHD): what have we learned?Cardiovascular safety of stimulants in children: findings from recent population-based cohort studies.Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need a SCOUT (trial)?Cardiac autonomic dysfunction and arterial stiffness among children and adolescents with attention deficit hyperactivity disorder treated with stimulants.Cardiovascular Safety of Concomitant Use of Atypical Antipsychotics and Long-Acting Stimulants in Children and Adolescents With ADHD.Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment.Assessment of Cardiovascular Risks due to Methylphenidate in Six Months of Treatment in Children with Attention Deficit and Hyperactivity Disorder

P2860

Q22250876-32469C75-121D-4831-85AD-005D99EF0199 Q22252794-E52728E9-6F12-4529-AFBE-48FDA84EA1E5 Q22253017-7F966824-1A7E-4A38-9468-17A681C18C09 Q24601949-FCE67CC4-CD3A-4078-8D9C-332A7D92E945 Q26822392-5CCCFA78-C3B1-466B-BC8C-7014CD75F680 Q28077862-AA9B55FA-E038-474C-857D-1F26A0C6AF3C Q33160890-6E0B3008-62CF-4847-B639-B180BC107CB6 Q34063584-9F42D840-E2F8-4314-BC4A-9EE8C8CB1F3E Q34220004-95C92405-ED18-407E-918F-9653420BA022 Q34280107-441154AC-BD60-4FF4-95E0-4D1FF5C79B08 Q34448884-A818FC4F-E30C-46AF-82B7-30788CF5B3DA Q34461113-A7FE5AC3-8062-4254-9111-DBBDA767CBE0 Q37893536-EFBC6027-3F98-4445-85F6-FAB2E592B88B Q38060572-5B8CDF84-8401-4CF6-9B37-C4946CD4C9CE Q38087534-987CB370-6F2E-474D-998C-D3FC26BFFBDF Q38126419-6D2FE38C-AFB0-40BC-93A5-6520E5D7A456 Q38242438-37BEF796-BD19-46BA-BE0A-3AAEC9E4025F Q40207017-B657E7C5-B083-4CD4-85CF-BA259E389D39 Q40400512-4EE40825-9656-461C-AB66-F04B1BCFA6E2 Q50800347-C01352AB-273F-4041-80CA-7E361053710D Q58276674-534CE020-670B-4D1C-BCAC-367A7C356F03

P2860

Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.

http://www.wikidata.org/entity/Q37376330

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.

@en

Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.

@nl

type

label

Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.

@en

Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.

@nl

prefLabel

Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.

@en

Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.

@nl

P1433

Q37376330-827AFE93-0133-4672-BF94-79C5CDC8E2A0

P1476

Q37376330-F445AA3A-CF6C-4910-A8C7-91023FCCC586

P2093

Q37376330-1044EF53-6AD7-49EC-8BAC-0A6DF056A7B3

Q37376330-967D0671-DFC8-4049-84E3-2DE8CF8EC98F

Q37376330-9BDE0CB5-B672-464E-9090-964013508AF6

Q37376330-BC77F7C7-DAEF-4384-87D8-4C4A5633299E

P2860

Q37376330-272E827B-8B0E-469D-9A07-BE3EDE26C27B

Q37376330-49F8CE16-3AA6-42F7-9D79-04321ACD795C

Q37376330-4B508CA2-B65C-4765-B105-202CD12A6570

Q37376330-7FAB2AFF-7120-45F0-B910-450ECDE3DF18

Q37376330-A9FB6232-8B78-4B36-ADC8-E5CB5667575E

Q37376330-AB7AE46C-5897-454C-B578-C1F486E03F69

Q37376330-CA2B4AC9-37C1-4675-89DB-A5A512315229

Q37376330-DA5357AE-4C3E-4A0C-B963-7DFCF1E30403

Q37376330-E00C4D37-EDA5-4938-AD70-EF71D21F6A95

Q37376330-E3E1C290-9201-48A3-AB2A-D3DC68249156

P304

Q37376330-34FFF8EF-DB58-4998-9838-36E6EAFBD270

P31

Q37376330-C145DB5B-2D65-4B0F-91EB-7A049F234D7D

P356

Q37376330-EDD15BB7-6650-4BFF-9767-3C11B6A9B7A1

P407

Q37376330-DA64D9A5-7372-4698-81F3-CFB1BE90E1A4

P433

Q37376330-5DD25247-55FD-409C-B442-82BF67E7772C

P478

Q37376330-10EAE4CC-F2EE-43DA-A1DC-2FFE687D5CB2

P577

Q37376330-B8F8A07D-D5F0-4378-9EEB-C1595E988881

P698

Q37376330-A7A36196-64FB-4CA7-8EC0-14D03F6A5BF6

P932

Q37376330-3152AB4A-552D-44FC-B7CA-E68C3EDF094C

P356

P1433

P1476

Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.

@en

P2093

Almut Gertrud Winterstein

http://www.w3.org/2001/XMLSchema#string

Arwa Saidi

http://www.w3.org/2001/XMLSchema#string

Jonathan Shuster

http://www.w3.org/2001/XMLSchema#string

Tobias Gerhard

http://www.w3.org/2001/XMLSchema#string

P2860

A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents

Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study.

Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial.

Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder.

Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder.

Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children.

Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial.

Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD.

Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database.

Evaluating medication effects outside of clinical trials: new-user designs.

P304

e75-80

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1542/PEDS.2008-3138

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P577

2009-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19564272

http://www.w3.org/2001/XMLSchema#string

P932

3856396

http://www.w3.org/2001/XMLSchema#string